Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What is the Anticipated CAGR of the Short Bowel Syndrome Market, and What Factors Will Drive It?
The market size of short bowel syndrome has experienced rapid expansion in the recent past. The projections estimate that it will rise from $2.69 billion in 2024 to reach $3.09 billion by 2025, indicating a compound annual growth rate (CAGR) of 14.9%. The historical growth has been influenced by factors such as the increasing incidence of gastrointestinal conditions, a surge in healthcare spending and insurance coverage, advancements in post-operative management of SBS, a rise in the prevalence of Crohn’s disease and other gastrointestinal disorders, and the enhancement of parental nutrition formulations and methods of administering them.
The market for short bowel syndrome is predicted to witness a significant surge in the size over the next couple of years, with an increase to $5.33 billion in 2029 and a compound annual growth rate (CAGR) of 14.6%. Factors propelling the market size during the forecast period include a growing occurrence of short bowel syndrome (SBS), an increase in the utilization of parenteral and enteral nutrition treatment, broadening clinical research, medication development, soaring health care expenditure, and improved awareness and early detection of SBS. The forecast period will also see major trends like progress in intestinal rehabilitation therapies, the creation of small intestine transplantation methods, the incorporation of telemedicine in managing SBS, technological evolutions in enteral feeding apparatus, and the use of artificial intelligence in planning treatment for SBS.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp
What External and Internal Drivers Are Contributing to the Growth of the Short Bowel Syndrome Market?
The escalating occurrence of digestive system illnesses is anticipated to foster the expansion of the short bowel syndrome market in the future. Digestive system diseases encompass a vast array of ailments that impair the digestive tract, including maladies that affect the stomach, intestines, liver, and pancreas, frequently resulting in hindered digestion and nutrient absorption. Unhealthy eating habits that negatively impact gut health and induce inflammation tend to drive the escalating occurrence of these diseases. When these diseases necessitate the surgical removal of damaged parts of the intestine, it could lead to the development of short bowel syndrome due to reduced absorption capacity. For example, in September 2023, as per the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization striving to enhance the quality of life of patients with Crohn’s disease and ulcerative colitis, with a prevalence of 825 per 100,000 in 2023, over 320,000 individuals in Canada are suffering from inflammatory bowel disease (IBD), and with an expected annual increase in prevalence by 2.44%, around 1.1% of the population, or 470,000 Canadians, will be estimated to have IBD by 2035. Thus, the escalating occurrence of digestive system diseases generates growth for the short bowel syndrome market.
What Segment Types Define the Short Bowel Syndrome Market Structure?
The short bowel syndrome market covered in this report is segmented –
1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine
2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis
3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels
Subsegments:
1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues
2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies
3) By Glutamine: Oral Glutamine, Intravenous Glutamine
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Short Bowel Syndrome Market?
North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Short Bowel Syndrome Market Over the Coming Years?
Primary businesses engaging in the short bowel syndrome market are concentrating their efforts on evolving medical science innovations, such as interventions for intestinal failure, to offer sophisticated therapeutic alternatives that enhance patient treatment outcomes with gastrointestinal illnesses. Intestinal failure is a severe disorder where the small intestine is unable to assimilate sufficient nutrients, fluids, and electrolytes necessary for suitable hydration and nutrition. In May 2024, for example, Ironwood Pharmaceuticals, Inc., a healthcare company based in the United States, revealed fresh data from studies analyzing apraglutide in adults with short bowel syndrome and intestinal failure (SBS-IF). Apraglutide, a next-generation GLP-2 analog, showed potentiality to boost intestinal absorption and lower dependence on parenteral support. The results emphasized the drug’s effectiveness, safety, and long-term advantages, mirroring Ironwood’s dedication to formulating innovative treatments for gastrointestinal ailments.
View the full report here:
https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report
What Is the Definition of the Short Bowel Syndrome Market?
Short bowel syndrome (SBS) is a malabsorption disorder caused by the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. It often results in diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of symptoms depends on the remaining intestinal length and its ability to adapt. SBS can significantly impact overall health, requiring careful dietary and medical management.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23515
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model